HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

374 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-24

Study Completion Date

2020-08-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a double-blinded, randomized placebo-controlled trial to determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily, for health care workers in the hospital reduces symptomatic and asymptomatic COVID-19 disease during the pandemic. 374 health care workers will be randomized at a 1:1 allocation between the intervention and placebo arms and followed for 90 days. The cumulative incidence of COVID-19 infection in the intervention group will be compared to the cumulative incidence of COVID-19 in the placebo group with relative (risk ratio and 95% CI) and absolute measures (risk difference and 95% CI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

NCT04333225

COVID-19

COMPLETED PHASE2

Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?

NCT04374942

Pre-Exposure Prophylaxis Coronavirus SARS-CoV 2

TERMINATED PHASE3

Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)

NCT04318015

COVID-19 Severe Acute Respiratory Syndrome

COMPLETED PHASE3

HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers

NCT04336748

Sars-CoV2 Infection Viral Healthcare Worker +1 more

WITHDRAWN PHASE3

Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic

NCT04331834

COVID-19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a double-blinded, randomized placebo-controlled trial to determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily, for health care workers in the hospital reduces symptomatic and asymptomatic COVID-19 disease during the pandemic.

Secondary outcomes include 1) Adverse events; 2) Duration of symptomatic COVID-19 disease; 3) Days hospitalized attributed to COVID-19; 4) Respiratory failure attributable to COVID-19 disease requiring i) non-invasive ventilation or ii) intubation/mechanical ventilation; 5) Mortality attributed to COVID-19 disease, and; 6) Number of days unable to work attributed to COVID-19. Laboratory markers within participants with confirmed COVID-19 will also be explored.

A total of 374 HCW will be randomized using a fixed 1:1 allocation ratio with randomization in permuted block of varying sizes from four to eight will be used to ensure equal allocation to each group. The study population will be health care workers at the New York Presbyterian Hospital - Cornell Campus and they will participate in the study for 90 days.

To determine if the intervention has been successful, the cumulative incidence of COVID-19 infection in the intervention group will be compared to the cumulative incidence of COVID-19 in the placebo group with relative (risk ratio and 95% CI) and absolute measures (risk difference and 95% CI). Investigators will also calculate adjusted risk ratios and risk differences including job class as a covariate and any other baseline clinical and demographic characteristics that are not balanced between the treatment and placebo arms using a log-binomial regression model.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prophylaxis COVID-19 Health Care Worker Hydroxychloroquine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

HCW are randomized to either the study drug (HCQ) or placebo.

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Participants in the study will be randomized to either the investigational drug (HCQ) or placebo. The investigational drug and placebo will have identical appearance and be taken at the same frequency and dosage. The administration of the drug and assessment will be blinded. Study arms will be unmasked at the end of the study for the final analysis.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydrocholoroquine Pre-exposure prophylaxis

HCQ will be administered as 400mg orally once for 60 days.

Group Type EXPERIMENTAL

Hydroxychloroquine Pre-Exposure Prophylaxis

Intervention Type DRUG

HCQ PreP 400mg daily

Placebo

Placebo will be administered as 400mg orally once for 60 days.

Group Type PLACEBO_COMPARATOR

Placebo oral tablet

Intervention Type DRUG

Placebo tablets 400mg daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydroxychloroquine Pre-Exposure Prophylaxis

HCQ PreP 400mg daily

Intervention Type DRUG

Placebo oral tablet

Placebo tablets 400mg daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Hydroxychloroquine PreP HCQ PreP Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Health care worker (HCW) at the hospital who work on a "full time" basis during the study period. For the purposes of the study, "health care workers" are physicians, nurses, nurse practitioners, physician assistants, respiratory therapists, X-ray technicians, social workers and support staff (including but not limited to house-keeping, and porters).
2. Age ≥18 years.
3. Ability to communicate with study staff in English

Exclusion Criteria

1. Known hypersensitivity/allergy to hydroxychloroquine or to 4-aminoquinoline compounds.
2. Current use of hydroxychloroquine for the treatment of a medical condition.
3. Known prolonged QT syndrome, or concomitant medications which simultaneously may prolong the QTC that cannot be temporarily suspended/replaced. These are including but not limited to Class IA, IC and III antiarrhythmics; certain antidepressants, antipsychotics, and anti-infectives; domperidone; 5-hydroxytryptamine (5-HT)3 receptor antagonists; kinase inhibitors; histone deacetylase inhibitors beta-2 adrenoceptor agonists.
4. Known pre-existing retinopathy of the eye.
5. Disclosure of self-administered use of hydroxychloroquine or chloroquine currently under investigation \<4 weeks prior to study. This window is intended to account for the drug half-life of HCQ (21 days).
6. Baseline symptom of COVID-19 disease at enrollment and baseline viral detection specimen positive for SARS-COV-2. All participants with COVID-19 symptoms at enrollment will be directed to have confirmatory testing (within the department or occupational health as per the site guidelines). Participants who are negative for SARS-COV-2 will be redirected to enrollment procedures, those testing positive will be excluded.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes